Long-term cost-utility analysis of a multidisciplinary primary care diabetes management program in Ontario

Canadian Journal of Diabetes

Volumn 31, Issue 3, 2007, Pages 205-214

  O'Reilly, Daria ^a,e   Hopkins, Robert ^a   Blackhouse, Gordon ^a   Clarke, Philip ^b   Hux, Janet ^c   Tarride, Jean Eric ^a   Dolovich, Lisa ^d   Goeree, Ron ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^e NONE   (Canada)

Author keywords

Cost utility analysis; Economic evaluation; Multidisciplinary diabetes management program; Ontario diabetes economic model

Indexed keywords

HEMOGLOBIN A1C;

ADULT; ARTICLE; CANADA; CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; IMMUNIZATION; MALE; MEDICAL SPECIALIST; NURSE; PATIENT EDUCATION; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION;

EID: 34948876435     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-2671(07)13007-0     Document Type: Article

References (27)

1. Provincial and Territorial Ministers of Health. Understanding Canada's Healthcare Costs: Final Report. Toronto, ON: Ontario Ministry of Health and Long-Term Care; 2000. Available at: http://www.health.gov.on.ca/english/public/ pub/ministry_reports/ptcd/ptcd_doc_e.pdf. Accessed August 15, 2007.
2. O'Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and Application to a Multidisciplinary Primary Care Diabetes Management Program. Hamilton, ON: Program for Assessment of Technology in Health (PATH); 2006. Available at: http://www.pathhta.ca/diabetes. pdf. Accessed August 15, 2007.
3. Diabetes Task Force. Report to the Ministry of Health and Long-Term Care. Toronto, ON: Ontario Ministry of Health and Long-Term Care; 2004. Available at: http://www.health.gov.on.ca/english/public/pub/ministry_reports/ diabetes_taskforce/ diabetes_taskforce.pdf. Accessed August 15, 2007.
4. Public Health Agency of Canada. Diabetes: Facts and Figures. Ottawa, ON: PHAC; 2003.
5. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
7. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med. 1996;124(1 Pt 2):127-130.
8. Klein R, Klein BE. Relation of glycemic control to diabetic complications and health outcomes. Diabetes Care. 1998;21 (suppl 3):C39-43.
9. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):136-145.
10. Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care. 2001;24:45-50.
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
13. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998;317:720-726.
14. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ. 2000;320:1373-1378.
15. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1997;20:725-734.
16. Dixon S, Currie CJ, Peters JR. The cost of diabetes: time for a different approach? Diabet Med. 2000;17:820-822.
17. Beale S, Bagust A, Shearer AT, et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2006;24 (suppl 1):21-34.
18. Lee H, Dolovich L, Ciliska D, et al. The Evaluation of the Continuity of Care at the Group Health Centre, a Unique Multi-specialty, Multi-disciplinary Health Service Organization. Ottawa, ON: Canadian Health Services Research Foundation; 2006. RC1-0301-06. Available at: http://www.chsrf.ca/final_research/ ogc/pdf/lee_final.pdf. Accessed August 15, 2007.
19. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ. 1998;159(suppl 8):S1-29.
20. Clarke PM, Gray AM, Briggs A, et al;UK Prospective Diabetes Study (UKPDS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747-1759.
21. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34:877-890.
22. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
23. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340-349.
24. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
25. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons; 1987.
26. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Macrovascular complications, dyslipidemia and hypertension. In: Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003;27(suppl 2):S58-S65.
27. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.